文献速递妇科肿瘤

按解剖累及与组织学分层的2023年国际妇产科联盟子宫内膜癌分期系统对生存结局的区分

Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer.
PubMed 文献 · Eur J Cancer · 2024-02-10

基于美国国家癌症数据库2004至2015年新诊断子宫腺癌患者134,677例,按2009与2023年FIGO分期系统分别分期并比较总生存。2023年分期下I期患者从96,161例降至70,101例(-27.1%,p<0.01),II期从9,295例增至36,294例(+390.5%,p<0.01)。似然比检验支持2023年系统(p=0.020),新分期分组可能提供更精确的预后判断。

要点

  • 2023年FIGO分期下I期患者从96,161例降至70,101例(-27.1%,p<0.01),II期从9,295例增至36,294例(+390.5%,p<0.01)。
  • 2023年IA3期(低危、同时性子宫内膜与卵巢肿瘤且存在克隆关系)10年OS为73.4%,2009年IIIA期为52.6%。
  • 2023年IIIB2期(盆腔腹膜受累,原2009年IVB期)10年OS为49.4%,2009年IVB期为18.7%。

核心结论

  • 采用FIGO 2023年子宫内膜癌解剖与组织学分期的背景下,分期迁移在早期疾病中最为明显,新分期分组可能提供更精确的预后判断,这些变化可能影响未来管理。

研究设计与样本

  • 查询美国国家癌症数据库(NCDB)2004至2015年新诊断子宫腺癌患者,随访数据延伸至2020年,共分析134,677例。
  • 分别按2009年和2023年FIGO分期系统确定分期,采用Kaplan-Meier估计和Cox比例风险模型进行生存分析。

主要发现

  • 按2023年分类,I期患者从96,161例降至70,101例(-27.1%,p<0.01),II期患者从9,295例增至36,294例(+390.5%,p<0.01)。
  • 2023年IA3期(低危、同时性子宫内膜与卵巢肿瘤且存在克隆关系)10年OS为73.4%,2009年IIIA期为52.6%。
  • 2023年IIIB2期(盆腔腹膜受累,原2009年IVB期)10年OS为49.4%,2009年IVB期为18.7%。

关键数值与推荐

  • 采用Akaike信息准则、贝叶斯信息准则和Harrel一致性指数评估各分期系统对所有分期的OS预后判断能力,似然比检验支持2023年系统(p=0.020)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer underwent revision in 2023, incorporating histology, lymphovascular space invasion, and molecular classification. Herein, we compare overall survival (OS) outcomes by anatomic and histologic involvement for patients staged by the 2009 system versus 2023 system. METHODS: The National Cancer Database (NCDB) was queried for patients with newly-diagnosed uterine adenocarcinoma from 2004 to 2015, with follow-up data extending through 2020. Stage was determined by both the 2009 and 2023 FIGO staging systems. Kaplan-Meier estimators and Cox proportional hazards models were used for survival analysis. RESULTS: A total of 134,677 patients were analyzed. Per 2023 classification, patients with stage I disease decreased from 96,161 to 70,101 (-27.1%, p < 0.01), while stage II disease increased from 9295 to 36,294 (+390.5%, p < 0.01). Greatest OS change was observed for 2023 stage IA3 patients (low-risk, synchronous endometrial and ovarian tumors with a clonal relationship), whose 10-year OS was 73.4%, compared to 52.6% for 2009 stage IIIA disease. Ten-year OS for 2023 stage IIIB2 (pelvic peritoneal involvement), previously 2009 stage IVB, was 49.4%, compared to 18.7% for 2009 stage IVB patients. Akaike information criterion, Bayesian information criterion, and Harrel's concordance index were used to evaluate OS prognostication of each staging system across all stages, with likelihood ratio favoring the 2023 system (p = 0.020). CONCLUSIONS: With FIGO's 2023 endometrial cancer anatomic and histologic staging system, stage migration is greatest in early-stage disease. New staging groups may offer more precise prognostication. These changes may affect future management.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gravbrot N, Weil CR, DeCesaris CM, et al. Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer. Eur J Cancer. 2024. PMID: 38377777. doi:10.1016/j.ejca.2024.113913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。